Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Cruel And Unusual Treatment, Carl Elliott, Charles Weijer
Cruel And Unusual Treatment, Carl Elliott, Charles Weijer
Charles Weijer
No abstract provided.
Monitoring Clinical Research: An Obligation Unfulfilled, Charles Weijer, Stanley Shapiro, Abraham Fuks, Kathleen Glass, Myriam Skrutkowska
Monitoring Clinical Research: An Obligation Unfulfilled, Charles Weijer, Stanley Shapiro, Abraham Fuks, Kathleen Glass, Myriam Skrutkowska
Charles Weijer
The revelation that data obtained for the US-based National Surgical Adjuvant Breast and Bowel Project (NSABP) from subjects enrolled at Hôpital Saint-Luc in Montreal was falsified has eroded public trust in research. Institutions can educate researchers and help prevent unethical research practices by establishing procedures to monitor research involving human subjects. Research monitoring encompasses four categories of activity: annual reviews of continuing research, monitoring of informed consent, monitoring of adherence to approved protocols and monitoring of the integrity of data. The authors describe characteristics of research projects that may call for monitoring procedures in each category. The form taken by …
Our Bodies, Our Science, Charles Weijer
The Breast Cancer Research Scandal: Addressing The Issues, Charles Weijer
The Breast Cancer Research Scandal: Addressing The Issues, Charles Weijer
Charles Weijer
The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.